CrystalGenomics Inc (083790) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.129x

Based on the latest financial reports, CrystalGenomics Inc (083790) has a cash flow conversion efficiency ratio of -0.129x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-11.39 Billion ≈ $-7.72 Million USD) by net assets (₩87.96 Billion ≈ $59.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 083790 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

CrystalGenomics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how CrystalGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

CrystalGenomics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CrystalGenomics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Killi Resources Ltd AU:KLI	-0.250x
Worth Peripherals Limited NSE:WORTH	0.067x
Athira Pharma Inc NASDAQ:ATHA	-0.698x
PLYTEC Holding Berhad KLSE:0289	0.064x
Syntara Ltd AU:SNT	-0.694x
Cue Biopharma NASDAQ:CUE	-0.681x
Mida Assets Public Company Limited BK:MIDA	-0.061x
Inmobiliaria Park Rose Iberoamericana SOCIMI SA MC:YPARK	0.003x

Annual Cash Flow Conversion Efficiency for CrystalGenomics Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of CrystalGenomics Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 083790 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩98.52 Billion ≈ $66.76 Million	₩-25.85 Billion ≈ $-17.52 Million	-0.262x	-17.63%
2023-12-31	₩145.29 Billion ≈ $98.46 Million	₩-32.41 Billion ≈ $-21.96 Million	-0.223x	-72.08%
2022-12-31	₩188.28 Billion ≈ $127.59 Million	₩-24.40 Billion ≈ $-16.54 Million	-0.130x	-135.12%
2021-12-31	₩207.84 Billion ≈ $140.85 Million	₩-11.46 Billion ≈ $-7.77 Million	-0.055x	+27.74%
2020-12-31	₩214.76 Billion ≈ $145.54 Million	₩-16.38 Billion ≈ $-11.10 Million	-0.076x	-59.32%
2019-12-31	₩149.05 Billion ≈ $101.01 Million	₩-7.14 Billion ≈ $-4.84 Million	-0.048x	-632.04%
2018-12-31	₩184.47 Billion ≈ $125.01 Million	₩-1.21 Billion ≈ $-817.78K	-0.007x	-136.69%
2017-12-31	₩91.59 Billion ≈ $62.07 Million	₩1.63 Billion ≈ $1.11 Million	0.018x	+117.86%
2016-12-31	₩83.16 Billion ≈ $56.36 Million	₩-8.30 Billion ≈ $-5.63 Million	-0.100x	-51.96%
2015-12-31	₩71.94 Billion ≈ $48.75 Million	₩-4.73 Billion ≈ $-3.20 Million	-0.066x	+3.72%
2014-12-31	₩55.03 Billion ≈ $37.29 Million	₩-3.75 Billion ≈ $-2.54 Million	-0.068x	--

About CrystalGenomics Inc

KQ:083790 Korea Pharmaceuticals

Market Cap

$26.59 Million

₩39.24 Billion KRW

Market Cap Rank

#24223 Global

#1687 in Korea

Share Price

₩970.00

Change (1 day)

+4.30%

52-Week Range

₩779.00 - ₩1925.00

All Time High

₩18365.04